Literature DB >> 19698857

Costs of excessive postoperative hemorrhage in cardiac surgery.

Michael C Christensen1, Stephan Krapf, Angela Kempel, Christian von Heymann.   

Abstract

BACKGROUND: Excessive postoperative hemorrhage in cardiac surgery is a serious clinical complication placing substantial demands on hospital resources. This study quantifies the exact impact of postoperative hemorrhage on hospital costs in Germany.
METHODS: We retrospectively analyzed data collected prospectively in the Quality Assurance Database at the Heart Center of the Klinikum Augsburg, Germany. All relevant perioperative data for resources consumption were analyzed and compared in patients with and without excessive postoperative hemorrhage in cardiac surgery. Multivariate regression analysis identified the incremental costs of postoperative hemorrhage while adjusting for potential confounding.
RESULTS: A total of 1118 patients had cardiac surgery between January and December 2006. Six percent were identified with excessive postoperative hemorrhage. The risk of experiencing a postoperative complication (including death) (P < .0001), returning to operating room for reexploration (P < .0001), staying in intensive care unit for longer than 72 hours (P < .0001), receiving ventilation for longer than 24 hours (P < .0001), and receiving any kind of postoperative blood transfusion (P < .0001) was significantly higher in patients with excessive postoperative hemorrhage. Twenty-two percent of patients with excessive postoperative hemorrhage died compared with 6% of the patients without excessive postoperative hemorrhage (P < .0001). When adjusting for potential confounding factors, the incremental costs of excessive postoperative hemorrhage was euro6251 (95% confidence interval, 4594-7909).
CONCLUSIONS: The average hospital costs related to excessive postoperative hemorrhage in cardiac surgery in Germany are substantial and associated with a significant risk of postoperative complications and death. Clinical interventions that can effectively prevent or address excessive postoperative hemorrhage in cardiac surgery are likely to have substantial cost-effectiveness potential.

Entities:  

Mesh:

Year:  2009        PMID: 19698857     DOI: 10.1016/j.jtcvs.2009.02.021

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  29 in total

1.  The effect of the perioperative blood transfusion and blood conservation in cardiac surgery Clinical Practice Guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices.

Authors:  Donald S Likosky; Daniel C FitzGerald; Robert C Groom; Dwayne K Jones; Robert A Baker; Kenneth G Shann; C David Mazer; Bruce D Spiess; Simon C Body
Journal:  J Extra Corpor Technol       Date:  2010-06

2.  TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage.

Authors:  Kevin Fleming; Roberta E Redfern; Rebekah L March; Nathan Bobulski; Michael Kuehne; John T Chen; Michael Moront
Journal:  J Extra Corpor Technol       Date:  2017-12

3.  Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.

Authors:  P Gueret; S Combe; C Krezel; E Fuseau; P L M van Giersbergen; M Petitou; E Neuhart
Journal:  Eur J Clin Pharmacol       Date:  2016-10-15       Impact factor: 2.953

4.  Bleeding Assessment Scale in Critically Ill Children (BASIC): Physician-Driven Diagnostic Criteria for Bleeding Severity.

Authors:  Marianne E Nellis; Marisa Tucci; Jacques Lacroix; Philip C Spinella; Kelly D Haque; Arabela Stock; Marie E Steiner; E Vincent S Faustino; Nicole D Zantek; Peter J Davis; Simon J Stanworth; Jill M Cholette; Robert I Parker; Pierre Demaret; Martin C J Kneyber; Robert T Russell; Paul A Stricker; Adam M Vogel; Ariane Willems; Cassandra D Josephson; Naomi L C Luban; Laura L Loftis; Stéphane Leteurtre; Christian F Stocker; Susan M Goobie; Oliver Karam
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

Review 5.  Massive bleeding in cardiac surgery. Definitions, predictors and challenges.

Authors:  A Petrou; P Tzimas; S Siminelakis
Journal:  Hippokratia       Date:  2016 Jul-Sep       Impact factor: 0.471

6.  Correlation of pre-operative plasma protein concentrations in cardiac surgery patients with bleeding outcomes using a targeted quantitative proteomics approach.

Authors:  Nathan Clendenen; Ashley Tollefson; Monika Dzieciatkowska; Alice Cambiaghi; Manuela Ferrario; Miranda Kroehl; Anirban Banerjee; Angelo D'Alessandro; Kirk C Hansen; Nathaen Weitzel
Journal:  Proteomics Clin Appl       Date:  2017-03-07       Impact factor: 3.494

7.  Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy.

Authors:  Klaus Görlinger; Dietmar Fries; Daniel Dirkmann; Christian F Weber; Alexander A Hanke; Herbert Schöchl
Journal:  Transfus Med Hemother       Date:  2012-03-08       Impact factor: 3.747

8.  Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study.

Authors:  Francesco Vasques; Luca Spiezia; Alberto Manfrini; Vincenzo Tarzia; Dario Fichera; Paolo Simioni; Gino Gerosa; Carlo Ori; Guido Di Gregorio
Journal:  J Anesth       Date:  2016-10-18       Impact factor: 2.078

9.  Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests: a single-institution propensity-adjusted cohort study.

Authors:  Qing Jia; Michael J Brown; Leanne Clifford; Gregory A Wilson; Mark J Truty; James R Stubbs; Darrell R Schroeder; Andrew C Hanson; Ognjen Gajic; Daryl J Kor
Journal:  Lancet Haematol       Date:  2016-02-18       Impact factor: 18.959

10.  Barriers and facilitators to implementing evidence based bleeding management in Australian Cardiac Surgery Units: a qualitative interview study analysed with the theoretical domains framework and COM-B model.

Authors:  Bronwyn L Pearse; Samantha Keogh; Claire M Rickard; Yoke L Fung
Journal:  BMC Health Serv Res       Date:  2021-06-05       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.